Purification of human plasminogen activator inhibitor (PAI-1) from Escherichia coli and separation of its active and latent forms by hydrophobic interaction chromatography

Fibrinolysis and Proteolysis

Volumn 9, Issue 4, 1995, Pages 215-221

  Kvassman, J O ^a   Shore, J D ^a  

^a Division of Biochemical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; RECOMBINANT PROTEIN;

ARTICLE; CHROMATOGRAPHY; DRUG STABILITY; ESCHERICHIA COLI; FLUORESCENCE; GENE EXPRESSION; METHODOLOGY; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN PURIFICATION;

EID: 0029134094     PISSN: 02689499     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(08)80062-8     Document Type: Article

References (25)

1. Cloning and sequence of a cDNA coding for the human β-migrating endothelial cell-type plasminogen activator inhibitor
2. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants
3. 1-antitrypsin for structure and function of serpins
4. Structural basis for latency in plasminogen activator inhibitor-1
5. Purification of active human plasminogen activator inhibitor 1 from Escherichia coli comparison with natural and recombinant forms purified from eucaryotic cells
6. Purification and characterization of active and stable recombinant plasminogen activator inhibitor accumulated at high levels in Escherichia coli
7. 1-proteinase inhibitor variants
8. 1-antitrypsin by a peptide sequentially similar to β-strand s4A
9. Conversion of antithrombin from an inhibitor of thrombin to a substrate with reduced heparin affinity and enhanced conformational stability by binding of a tetradecapeptide corresponding to the P1 to P14 region of the putative reactive bond loop of the inhibitor
10. 1-proteinase inhibitor variant T345R. Influence of P14 residue on substrate and inhibitory pathways
11. Serpin reactive-center loop mobility is required for inhibition function but not for enzyme recognition
12. Bovine plasminogen activator inhibitor 1: specificity determinations and comparison of the active, latent and guanidine-activated forms
13. The geometry of the reactive site and of the peptide groups in trypsin trypsinogen and its complexes with inhibitors
14. A frameshift mutation resulting in complete plasminogen activator inhibitor-1 (PAI-1) deficiency
15. Molecular mechanisms in the hormone regulation of plasminogen activator activity in ovarian granulosa cells and cumulusoolyte complexes
16. Plasminogen activators tissue degradation and cancer
17. Membrane and matrix localization of proteinases: a common theme in tumor cell invasion and angiogenesis
18. Cell-associated plasminogen activation: regulation and physiological functions
19. Purification and characterization of active and latent forms of recombinant plasminogen activator inhibitor 1 produced in Escherichia coli
20. Stability of plasminogen activator inhibitor (PAI-1)
21. The pH-dependence of the active to latent transition in PAI-1
22. Purification of high and low molecular weight plasminogen activator inhibitor 1 from fibrosarcoma cell-line HT 1080 conditioned medium
23. Expression of human plasminogen activator inhibitor type-1 (PAI-1) in Escherichia coli as a soluble protein comprised of active and latent forms. Isolation and crystallization of latent PAI-1
24. Dynamic and structural relationships in recombinant plasminogen activator inhibitor-1 (rPAI-1)
25. Separation of Active and Inactive Forms of Recombinant Human Plasminogen Activator Inhibitor Type 1 (PAI-1) Expressed in Chinese Hamster Ovary Cells: Comparison with Native Human PAI-1